Amblyopia in 2026: definitions, diagnosis, treatment, and emerging therapies

ABSTRACT

Amblyopia is a leading, yet largely preventable, cause of visual impairment and is now recognized as a binocular neurodevelopmental disorder characterized by interocular suppression and widespread functional deficits. This narrative review synthesizes contemporary evidence on the epidemiology, pathophysiology, diagnosis, and management of amblyopia, with a focus on clinically applicable guidance. Conventional treatments—including optimal refractive correction, occlusion therapy, and pharmacologic penalization with atropine—remain highly effective when appropriately prescribed, titrated, and monitored for adherence, even among selected older children. Emerging binocular approaches, such as dichoptic digital therapies, perceptual learning, and short-term monocular deprivation, aim to restore binocular balance. Although these strategies may yield improvements in stereopsis and contrast sensitivity, their effects are generally modest and task-specific. Overall, current evidence supports the integration of traditional and novel approaches into etiology-specific, measurement-driven care pathways. Future research should prioritize functional outcomes, long-term durability, and real-world effectiveness.

Keywords: Amblyopia/diagnosis; Amblyopia/physiopathology; Amblyopia/epidemiology; Binocular vision; Vision disorders; Review

THE CONTENT OF THIS ARTICLE IS NOT AVAILABLE FOR THIS LANGUAGE.